Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bradley Theodore Hyman, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Bradley Hyman and Simon Dujardin.
Connection Strength

5.090
  1. Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2021 Feb; 27(2):356.
    View in: PubMed
    Score: 0.952
  2. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2020 08; 26(8):1256-1263.
    View in: PubMed
    Score: 0.912
  3. Tau Prion-Like Propagation: State of the Art and Current Challenges. Adv Exp Med Biol. 2019; 1184:305-325.
    View in: PubMed
    Score: 0.824
  4. Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases. Brain Commun. 2021; 3(2):fcab096.
    View in: PubMed
    Score: 0.242
  5. Synaptic and metabolic gene expression alterations in neurons that are recipients of proteopathic tau seeds. Acta Neuropathol Commun. 2020 10 19; 8(1):168.
    View in: PubMed
    Score: 0.233
  6. Tau reduction in aged mice does not impact Microangiopathy. Acta Neuropathol Commun. 2020 08 18; 8(1):137.
    View in: PubMed
    Score: 0.231
  7. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron. 2019 Jan 16; 101(2):349.
    View in: PubMed
    Score: 0.207
  8. Tau impairs neural circuits, dominating amyloid-ß effects, in Alzheimer models in vivo. Nat Neurosci. 2019 01; 22(1):57-64.
    View in: PubMed
    Score: 0.205
  9. Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol Commun. 2018 11 29; 6(1):132.
    View in: PubMed
    Score: 0.205
  10. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron. 2018 09 05; 99(5):925-940.e7.
    View in: PubMed
    Score: 0.201
  11. Tau reduction in the presence of amyloid-ß prevents tau pathology and neuronal death in vivo. Brain. 2018 07 01; 141(7):2194-2212.
    View in: PubMed
    Score: 0.199
  12. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 2018 04 03; 37(7).
    View in: PubMed
    Score: 0.194
  13. Enhanced Tau Aggregation in the Presence of Amyloid ß. Am J Pathol. 2017 Jul; 187(7):1601-1612.
    View in: PubMed
    Score: 0.184
  14. Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. J Neuropathol Exp Neurol. 2021 Sep 08.
    View in: PubMed
    Score: 0.062
  15. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J Biol Chem. 2021 Jan-Jun; 296:100715.
    View in: PubMed
    Score: 0.060
  16. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. J Neurosci. 2021 May 12; 41(19):4335-4348.
    View in: PubMed
    Score: 0.060
  17. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathol. 2021 02; 141(2):217-233.
    View in: PubMed
    Score: 0.059
  18. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease. Cell. 2020 12 10; 183(6):1699-1713.e13.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.